Voyager Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.3%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$39.3Mnext fiscal year
FY EPS (est.)
-$1.66next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly171.7MTarget: Sufficient to fund planned operations into 2028
Collaboration Revenue Quarterly2.6MTarget: Variable based on partner milestones and research reimbursements
Research and Development (R&D) Expenses Quarterly24.6MTarget: Managed efficiently while advancing lead programs
Watch Items
- VY1706 Clinical Trial InitiationTrigger: First-in-human dosing in Alzheimer's disease patientsAction: Monitor FDA IND clearance and H2 2026 trial launch progress
- VY7523 Tau PET Imaging DataTrigger: Efficacy data readout from multiple ascending dose (MAD) trialAction: Evaluate clinical efficacy and safety signals in H2 2026
- NBIB-223 Clinical Trial InitiationTrigger: Partner Neurocrine Biosciences initiating clinical trial in Friedreich's ataxiaAction: Track FDA IND clearance and H2 2026 trial initiation
Research as of 20 Jun 2026